Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.44 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878806 | 0.78 | CSF1R (0.61) | LCKLYNHCKSRCBRAF | |
| SCHEMBL13878804 | 0.78 | BRAF (0.60) | LCKINSRLYNHCKSRC | |
| SCHEMBL13878805 | 0.78 | LYN (0.55) | LCKINSRLYNHCKSRC | |
| SCHEMBL1704383 | 0.76 | MAPK14 (0.53) | LCKINSRLYNHCKSRC | |
| SCHEMBL4257822 | 0.76 | SCN9A (0.43) | LCKINSRLYNHCKSRC | |
| SCHEMBL13878808 | 0.76 | MAPT (0.75) | LCKSRCBRAFMAPTPOLB | |
| SCHEMBL4257816 | 0.75 | BTK (0.42) | LCKINSRLYNHCKSRC | |
| SCHEMBL13878794 | 0.75 | LCK (0.55) | LCKBRAFMAPTPOLBAPEX1 | |
| SCHEMBL13878816 | 0.74 | KIT (0.62) | BRAFCSF1RKIT | |
| SCHEMBL13292010 | 0.73 | LYN (0.52) | LCKINSRLYNHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | LCK 56/4885INSR 1466/4885LYN 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.